

July 3, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Press Release.

Dear Sir / Madam,


We enclose herewith a copy of press release dated July 3, 2018 titled "Zydus receives final approval from the USFDA for Nifedipine Extended-Release Tablets USP and Cholestyramine for Oral Suspension USP."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Nifedipine Extended-Release Tablets USP and Cholestyramine for Oral Suspension USP

Ahmedabad, 03 July, 2018

Zydus Cadila has received the final approval from the USFDA to market Nifedipine Extended-Release Tablets USP (Adalat[®] CC) in the strengths of 30 mg, 60 mg, and 90 mg. It is used to treat high blood pressure and angina (chest pain brought on by exercise or stress). It works to control blood pressure and reduce the number of angina attacks by relaxing blood vessels. It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

The group also received the final approval to market Cholestyramine for Oral Suspension USP (Questran[®]), 4 g resin per pouch or scoopful. It is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. It will be manufactured at the group's formulations manufacturing facility at Baddi.

In line with this, the group now has 201 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
